Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
Metrics to compare | ACELP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACELPPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.6x | −9.4x | −0.5x | |
PEG Ratio | −0.12 | −0.20 | 0.00 | |
Price/Book | 9.7x | 6.5x | 2.6x | |
Price / LTM Sales | - | 41.8x | 3.3x | |
Upside (Analyst Target) | 34.0% | 17.7% | 40.6% | |
Fair Value Upside | Unlock | 14.3% | 5.3% | Unlock |